Pulmonary embolism · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether vitamin K antagonist (VKA) changes pulmonary embolism compared with low molecular weight heparin (LMWH) (very low certainty).
2 findings from 1 review
Major bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Minor bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether vitamin K antagonist (VKA) changes minor bleeding compared with low molecular weight heparin (LMWH) (very low certainty).
1 finding from 1 review
Minor bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
Vitamin K antagonist (VKA) showed no clear difference in all‐cause mortality (up to 3 months) compared with no VKA (low certainty).
1 finding from 1 review
Symptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
Vitamin K antagonist (VKA) showed no clear difference in symptomatic catheter‐related thrombosis (up to 3 months) compared with no VKA (low certainty).
1 finding from 1 review
Symptomatic catheter‐related thrombosis measured as asymptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
It is very uncertain whether vitamin K antagonist (VKA) changes symptomatic catheter‐related thrombosis measured as asymptomatic… compared with no VKA (very low certainty).
1 finding from 1 review
Major bleeding · people with cancer with thrombosis prophylaxis and central venous catheters
Vitamin K antagonist (VKA) showed no clear difference in major bleeding (up to 3 months) compared with no VKA (low certainty).
1 finding from 1 review
Minor bleeding · people with cancer with thrombosis prophylaxis and central venous catheters
Vitamin K antagonist (VKA) showed no clear difference in minor bleeding (up to 3 months) compared with no VKA (low certainty).
1 finding from 1 review
Antibiotic versus heparin only lock/flush solution: catheter‐related infections · people with cancer with thrombosis prophylaxis and central venous catheters
Vitamin K antagonist (VKA) showed no clear difference in catheter‐related infection (3 months) compared with no VKA (low certainty).
1 finding from 1 review
Premature CVC removal (3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
Vitamin K antagonist (VKA) showed no clear difference in premature CVC removal (3 months) compared with no VKA (low certainty).
1 finding from 1 review
Outcomes ( · people with cancer with thrombosis prophylaxis and central venous catheters
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Serum vitamin D (25(OH)D): ECC vs caries-free
The intervention led to lower serum vitamin D (25(OH)D): ECC vs caries-free; GRADE not reported.
1 finding from 1 review
Prenatal vitamin D deficiency prevalence · pregnant women
The review reported a pooled prenatal vitamin D deficiency prevalence of 32%.
1 finding from 1 review
Proportion 0.32
Studies not reported
GRADE not reported
Intervention not reported
Serum vitamin D (25(OH)D): ECC vs caries-free
The intervention led to lower serum vitamin D (25(OH)D): ECC vs caries-free; GRADE not reported.
1 finding from 1 review
Serum 25-hydroxyvitamin D level · Preschool children ≤6 years, Asia
In Asia, children with S-ECC had lower serum 25(OH)D than caries-free children (WMD -19.25 nmol/l; ungraded).
1 finding from 1 review
Intervention not reported
Serum vitamin D (25(OH)D): ECC vs caries-free
The intervention led to lower serum vitamin D (25(OH)D): ECC vs caries-free; GRADE not reported.
1 finding from 1 review
Intervention not reported
Serum vitamin D (25(OH)D): ECC vs caries-free
The intervention led to lower serum vitamin D (25(OH)D): ECC vs caries-free; GRADE not reported.
1 finding from 1 review
Serum 25-hydroxyvitamin D level · Preschool children ≤6 years, North America
In North America, children with S-ECC had lower serum 25(OH)D than caries-free children (WMD -13.28 nmol/l; ungraded).
1 finding from 1 review
Serum 25-hydroxyvitamin D level · Children aged 6 years or younger (preschool children)
Children with severe ECC had significantly lower serum 25(OH)D than caries-free children (WMD -18.64 nmol/l; ungraded).
1 finding from 1 review